Health & Fitness
A Prelude to a Cure
How one man became a pioneer, fighting aggressive prostate cancer with a revolutionary pre-surgery therapy in the PRELUDE trial.
This is a paid post contributed by a Patch Community Partner. The views expressed in this post are the author's own, and the information presented has not been verified by Patch.
For 66-year-old chemical engineer John Frotton, a few simple numbers delivered a life-altering diagnosis: aggressive prostate cancer. Even with the standard treatment, a grim statistic loomed—a high chance the cancer could return.
But what if you could attack the cancer before it was even removed?
In a groundbreaking move, John became the very first patient to enroll in the PRELUDE Trial at Hackensack University Medical Center's John Theurer Cancer Center. Led by Nitin K. Yerram, M.D. this revolutionary study deploys a "microscopic heat-seeking missile" therapy to destroy cancer cells prior to surgery, aiming to stop a recurrence before it can even start.
Discover how being a pioneer in this innovative trial gave John more than just a new treatment—it gave him peace of mind and a powerful glimpse into the future of cancer care.
Click to read the full story of his incredible journey.
This post is an advertorial piece contributed by a Patch Community Partner, a local brand partner. To learn more, click here.
